U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. Tobacco Products
  3. Tobacco Science & Research
  4. Research
  5. The Human Dose-Response Effects of Methyl Salicylate in Smokeless Tobacco
  1. Research

The Human Dose-Response Effects of Methyl Salicylate in Smokeless Tobacco

Principal Investigator(s): Bortosz Koszowski and Mollie Miller  
    
Funding Mechanism: Research Contract

ID number: HHSF223201710040I

Award Date: 9/30/2019

Institution: Battelle

The goals of this project are to determine how changes in the methyl salicylate content of smokeless tobacco may affect HPHC exposure and nicotine pharmacokinetics (the body’s effects on nicotine), as well as to determine how changes in methyl salicylate content affect nicotine pharmacodynamics (nicotine’s effects on the body) and abuse liability. First, researchers will amend commercially available smokeless tobacco to create four investigational smokeless tobacco products (no methyl salicylate and low, medium, and high methyl salicylate content ranging from 0.3-30 mg/g). Next, researchers will administer each of the four products to 56 adult smokeless tobacco users (aged 21-65) under specific use conditions. Researchers will measure heart rate, blood pressure, pharmacokinetics, exposure to harmful and potentially harmfully constituents (HPHCs), and abuse liability (measures of liking, craving, and withdrawal) before and after product use. Findings may inform future regulatory activities related to smokeless tobacco products.  
 

Back to Top